Ketoconazole drug data and news

---

Sudden Akathisia After a Ziprasidone Dose Reduction  Mar 2, 2006
We report five cases of akathisia in female patients with bipolar disorder (who were treated with 80–160 mg/day of ziprasidone) that appeared to occur ... - Am J Psychiatry (subscription)

Stephan Heres, MD , John Davis, MD , Katja Maino, MD , Elisabeth ...  Feb 9, 2006
...trials comparing the second-generation antipsychotics aripiprazole, amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, and ziprasidone. ... - Am J Psychiatry (subscription)

Myocarditis During Clozapine Treatment  Feb 14, 2006
Because of these adverse effects, Mr. A’s psychiatric medications were discontinued, and ziprasidone was titrated to 40 mg bid 6 months before admission. ... - Am J Psychiatry (subscription)

Personal Accounts: Scaling Mount Rushmore: Cartography of a Manic ...  Feb 14, 2006
...quetiapine. Was there a new drug? In fact, there was, one called ziprasidone. Most people are in a hurry to get out of a psychiatric ward. ... - Psychiatric Services (subscription)

Sudden cardiac death and antipsychotics. Part 1: Risk factors and ...  Feb 9, 2006
Droperidol, sertindole and ziprasidone extend the QT interval by an average of 15–35 ms; quetiapine, haloperidol and olanzapine by 5 ms, to 15 ms. ... - Adv Psychiatric Treat (subscription)

Stephan Heres, MD , John Davis, MD , Katja Maino, MD , Elisabeth ...  09 Feb 2006
...trials comparing the second-generation antipsychotics aripiprazole, amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, and ziprasidone. ... - Am J Psychiatry (subscription)

Sudden cardiac death and antipsychotics. Part 1: Risk factors and ...  09 Feb 2006
Droperidol, sertindole and ziprasidone extend the QT interval by an average of 15–35 ms; quetiapine, haloperidol and olanzapine by 5 ms, to 15 ms. ... - Adv Psychiatric Treat (subscription)

Patient- and Facility-Level Factors Associated With Diffusion of a ...  Jan 25, 2006
This study evaluated the influence of patient- and facility-level characteristics on the early use of a new antipsychotic, ziprasidone, among Department of ... - Psychiatric Services (subscription)

CATIE Phase I Helps Clinicians Tailor Schizophrenia Treatment  Jan 12, 2006
...four of the second-generation or atypical antipsychotics (olanzapine [Zyprexa], quetiapine [Seroquel], risperidone [Risperdal] and ziprasidone [Geodon]) and ... - Psychiatric Times,

High-Cost Use of Second-Generation Antipsychotics Under ...  Jan 25, 2006
Prescription rates for first-line second-generation antipsychotics (risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole) have increased ... - Psychiatric Services (subscription)

People Can Suffer from Bipolar Disorder for Years until It is ...  Jan 30, 2006
Chapter 8 A Comparison of Second Generation Antipsychotics in the Treatment of Bipolar Disorder: Focus on Clozapine, Quetiapine, Ziprasidone and Aripiprazole ... - Genetic Engineering News,

Brief Reports: Patterns of Psychotropic Medication Use by Race ...  Jan 25, 2006
...molindone. Second-generation antipsychotics included clozapine, olanzapine, aripiprazole, quetiapine, risperidone, and ziprasidone. ... - Psychiatric Services (subscription)

We need more studies like CATIE - says Principal Investigator  Jan 11, 2006
...assigned to one of four newer, 'atypical' antipsychotics: olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), and ziprasidone (Geodon); or to ... - Pharma Times (subscription),

Lundbeck gets first nod for revived schizophrenia drug  Jan 18, 2006
...marketing potential remains to be seen, but a link to QT elevations has not proved a major problem for another schizophrenia drug, Pfizer's Geodon (ziprasidone ... - Pharma Times (subscription),

Prevalence of the Night Eating Syndrome in a Psychiatric ...  Jan 24, 2006
Atypical antipsychotic agents (which included aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone) were used more frequently by night eaters ... - Am J Psychiatry (subscription)

Interpreting the Results of the CATIE Study  Jan 7, 2006
The CATIE results showed that olanzapine, perphenazine, quetiapine, risperidone, and ziprasidone differ from one another somewhat in terms of efficacy and ... - Psychiatric Services (subscription)

Ziprasidone Effective in Children and Adolescents with Bipolar ...  Nov 11, 2005
11, 2005 -- Children and adolescents who are experiencing the manic phase of bipolar disorder benefit from treatment with ziprasidone (Geodon), according to ... - DG News

International Approvals: Zeldox, Alfimeprase, Bronchitol  Nov 15, 2005
Nov. 15, 2005 — The European Commission has approved a new indication for ziprasidone HCl capsules, allowing their use for the treatment of manic or mixed ... - Medscape (subscription)

Generic Forms of Janssen's Risperdal and Pfizer's Geodon Not ...  Nov 22, 2005
...care physicians (PCPs) and psychiatrists expect the launch of generic forms of Janssen's Risperdal (risperidone) and Pfizer's Geodon (ziprasidone) to increase ... - PharmaLive.com (press release),

Shire/Noven Daytrana Second-Line? Physicians Should Consider Oral ...  Dec 2, 2005
The committee said the language should follow the example of Pfizer’s Geodon (ziprasidone) labeling, which urges consideration of other antipsychotic ... - FDA Advisory Committee

Secondary Mania in Older Adults  Nov 13, 2005
Paradoxically, several atypical antipsychotics (olanzapine, risperidone, quetiapine, and ziprasidone), which are approved for treatment of bipolar disorder and ... - Am J Psychiatry (subscription)

Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind ...  Oct 2, 2005
...and John M. Kane, MD. OBJECTIVE: The efficacy and safety of olanzapine were compared with those of ziprasidone. METHOD: This was a ... - Am J Psychiatry (subscription)

Behavioral and Pharmacologic Treatment of Aggression in Children ...  Oct 3, 2005
Clozapine (Clozaril), quetiapine (Seroquel), olanzapine (Zyprexa) and ziprasidone (Geodon) have been evaluated in small or uncontrolled studies and case ... - Psychiatric Times,

Effectiveness of Antipsychotic Drugs in Patients with Chronic ...  Sep 24, 2005
...to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary ... - New England Journal of Medicine (subscription),

NIMH study to guide treatment choices for schizophrenia  Sep 19, 2005
...an older medication (perphenazine), available since the 1950s, to four newer medications (olanzapine, quetiapine, risperidone, and ziprasidone), introduced in ... - Medical News Today (press release),

According to non-industry study, Zyprexa(R) is more effective in ...  Sep 21, 2005
...the median time to discontinuation was 9.2 months as compared with 4.6 months for quetiapine, 4.8 months for risperidone, 3.5 months for ziprasidone and 5.6 ... - ArriveNet (press release),

Schizophrenia Drugs Still Fall Short  Sep 19, 2005
...were randomly assigned to receive various doses of perphenazine (a first-generation drug), olanzapine, quetiapine, risperidone or ziprasidone (all second ... - Forbes

Old antipsychotic drugs comparable to new drugs, study finds  Sep 20, 2005
...the older drug perphenazine or one of four atypicals: olanzapine (brand name Zyprexa), quetiapine (Seroquel), risperidone (Risperdal) or ziprasidone (Geodon). ... - Seattle Times,

Why New Drugs Don't Live Up to the Hype  Sep 30, 2005
Zyprexa was out, and she was moved to Geodon (ziprasidone), another newfangled antipsychotic, which made her feel antsy at first but works quite well. ... - CNN

Schizophrenia Drugs Still Fall Short  Sep 19, 2005
...were randomly assigned to receive various doses of perphenazine (a first-generation drug), olanzapine, Quetiapine, Risperidone or Ziprasidone (all second ... - HealthCentral.com

Newer antipsychotic not always better  Sep 27, 2005
Patients on other second-generation drugs quetiapine, risperidone and the new agent ziprasidone also had higher discontinuation rates than those on olanzapine. ... - AustralianDoctor.com (subscription),

Old and New Schizophrenia Drugs: Study Shows Patient Satisfaction ...  Sep 26, 2005
It was also lower than the rates for the new drugs, Seroquel (quetiapine) at 82 percent, and Geodon (ziprasidone) at79 percent. ... - PharmExec.com,

Most newer schizophrenia drugs no better - study  Sep 19, 2005
...from AstraZeneca Plc ; Risperdal (risperidone) from Janssen Pharmaceutica, a wholly owned unit of Johnson & Johnson ; Geodon (ziprasidone) from Pfizer Inc. ... - Reuters AlertNet,

Differences seen in anti-psychotic drugs  Sep 19, 2005
...were able to complete the trial, along with only 25 percent of the 257 patients on perphenazine, 21 percent of the 183 patients on ziprasidone, and 18 percent ... - Monsters and Critics.com,

Most newer schizophrenia drugs no better - study  Sep 19, 2005
...among the other four drugs: Seroquel (quetiapine) from AstraZeneca Plc ; Risperdal (risperidone) from Johnson & Johnson ; Geodon (ziprasidone) from Pfizer Inc. ... - Reuters AlertNet,

Most newer schizophrenia drugs no better - study  Sep 20, 2005
...than the other four. But still, 64 percent stopped taking it after 18 months. (ziprasidone) from Pfizer Inc. (PFE.N: Quote, Profile ... - Reuters

Zyprexa Edges Four Other Agents With Modest Benefit for ...  Sep 19, 2005
Zyprexa arm than was observed among patients randomized Trilafon (perphenazine) - the first generation comparator arm - or to Geodon (ziprasidone) the newest ... - CNN

Royal Dutch Shell to Restructure  Sep 20, 2005
...the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine (Astrazeneca's Seroquel), risperidone, and ziprasidone ... - BusinessWeek

Study: Old medication as effective as new for treating ...  Sep 19, 2005
...older drug, Trilafon (perphenazine), was just as effective as three newer antipsychotics, Seroquel (quetiapine), Risperdal (risperidone) and Geodon (ziprasidone ... - Kansas City Star,

Old schizophrenia drugs as good as new  Sep 20, 2005
In the study, each patient was randomly assigned to take one of the five medications: perphanazine, olanzapine, quetiapine, risperidone, and ziprasidone. ... - myDNA.com,

Antipsychotic Drugs for Schizophrenia  Sep 20, 2005
Throughout the study, 1,493 adults with schizophrenia received perphenazine or olanzapine, quetiapine, risperidone or ziprasidone for up to 18 months. ... - Ivanhoe

Duke, UNC authors say schizophrenia, depression drugs aren't much ...  Sep 19, 2005
...perphenazine -- now sold only as a generic medication -- to four newer drugs: olanzapine, quetiapine (Seroquel), risperidone (Risperdal) and ziprasidone (Geodon ... - Durham Herald Sun,

Schizophrenia: CATIE study compares the effectiveness and side ...  Sep 25, 2005
...older medication ( Perphenazine ), available since the 1950s, to four newer medications ( Olanzapine, Quetiapine, Risperidone, and Ziprasidone ), introduced in ... - Xagena.it,

Eli Lilly: double-edged results for Zyprexa  Sep 23, 2005
...namely Zyprexa (olanzapine), Johnson & Johnson's Risperdal (risperidone), AstraZeneca's Seroquel (quetiapine) and Pfizer's Geodon (ziprasidone), as well as the ... - Pharmaceutical Business Review

Many meds don't mix with the sun  Sep 21, 2005
Compa-zine), quetiapine (Seroquel), risperidone (Risperdal), thioridazine (Mellaril), thiothixene (Navane), trifluoperazine (Stelazine), ziprasidone (Geodon). ... - Pioneer Press,

Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system. Coadministration of NIZORAL^® Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects. Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary. The following drug interactions have been identified involving NIZORAL^® Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system:

Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite. The increased plasma concentration of terfenadine or its metabolite may result in prolonged QT intervals.

Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals. Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.

Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride. Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG. Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.

Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs. Dosage adjustment may be required if cyclosporine, tacrolimus, or methylprednisolone are given concomitantly with NIZORAL^® Tablets.

Coadministration of NIZORAL^® Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. These agents should not be used in patients treated with NIZORAL^® Tablets. If midazolam is administered parenterally, special precaution is required since the sedative effect may be prolonged.

Rare cases of elevated plasma concentrations of digoxin have been reported. It is not clear whether this was due to the combination of therapy. It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.

When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs. In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.

Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.

Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs. It is suggested to monitor both ketoconazole and phenytoin.

Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter. INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely. These drugs should not be given concomitantly.

After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and C_max of loratadine averaged 302% (± 142 S.D.) and 251% (± 68 S.D.), respectively, of those obtained after co-treatment with placebo. The AUC and C_max of descarboethoxyloratadine, an active metabolite, averaged 155% (± 27 S.D.) and 141% (± 35 S.D.), respectively. However, no related changes were noted in the QT₀ on ECG taken at 2, 6, and 24 hours after the coadministration. Also, there were no clinically significant differences in adverse events when loratadine was administered with or without ketoconazole.

Rare cases of a disulfiram-like reaction to alcohol have been reported. These experiences have been characterized by flushing, rash, peripheral edema, nausea, and headache. Symptoms resolved within a few hours.